Morgan Stanley’s PAVmed PAVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $968 | Sell |
163
-2
| -1% | -$14 | ﹤0.01% | 7516 |
|
|
2026
Q1 | $1.68K | Buy |
165
+4
| +2% | +$38 | ﹤0.01% | 7358 |
|
|
2025
Q4 | $1.07K | Sell |
161
-7
| -4% | -$80 | ﹤0.01% | 7350 |
|
|
2025
Q3 | $2.17K | Hold |
168
| – | – | ﹤0.01% | 7288 |
|
|
2025
Q2 | $3.02K | Buy |
168
+8
| +5% | +$160 | ﹤0.01% | 7146 |
|
|
2025
Q1 | $3.46K | Hold |
160
| – | – | ﹤0.01% | 7074 |
|
|
2024
Q4 | $3.01K | Sell |
160
-1
| -0.6% | -$30 | ﹤0.01% | 7117 |
|
|
2024
Q3 | $5.95K | Sell |
161
-8
| -5% | -$245 | ﹤0.01% | 6859 |
|
|
2024
Q2 | $4.13K | Sell |
169
-2
| -1% | -$100 | ﹤0.01% | 6898 |
|
|
2024
Q1 | $11K | Buy |
171
+85
| +99% | +$6.43K | ﹤0.01% | 6668 |
|
|
2023
Q4 | $10.6K | Sell |
86
-39
| -31% | -$4.6K | ﹤0.01% | 6639 |
|
|
2023
Q3 | $16.6K | Sell |
125
-53
| -30% | -$8.22K | ﹤0.01% | 6543 |
|
|
2023
Q2 | $32.7K | Sell |
178
-45
| -20% | -$9K | ﹤0.01% | 6374 |
|
|
2023
Q1 | $37.5K | Sell |
223
-73
| -25% | -$15.4K | ﹤0.01% | 6389 |
|
|
2022
Q4 | $64K | Sell |
296
-101
| -25% | -$38.1K | ﹤0.01% | 6183 |
|
|
2022
Q3 | $154K | Sell |
397
-147
| -27% | -$83.3K | ﹤0.01% | 5857 |
|
|
2022
Q2 | $229K | Sell |
544
-459
| -46% | -$222K | ﹤0.01% | 5829 |
|
|
2022
Q1 | $596K | Sell |
1,003
-1,485
| -60% | -$1.1M | ﹤0.01% | 5301 |
|
|
2021
Q4 | $2.75M | Sell |
2,488
-44
| -2% | -$95.6K | ﹤0.01% | 4311 |
|
|
2021
Q3 | $9.73M | Buy |
2,532
+829
| +49% | +$2.61M | ﹤0.01% | 2924 |
|
|
2021
Q2 | $4.91M | Buy |
1,703
+370
| +28% | +$874K | ﹤0.01% | 3797 |
|
|
2021
Q1 | $2.66M | Buy |
1,333
+434
| +48% | +$653K | ﹤0.01% | 4037 |
|
|
2020
Q4 | $857K | Buy |
899
+647
| +257% | +$553K | ﹤0.01% | 4755 |
|
|
2020
Q3 | $202K | Sell |
252
-1
| -0.4% | -$890 | ﹤0.01% | 5115 |
|
|
2020
Q2 | $240K | Buy |
253
+123
| +95% | +$123K | ﹤0.01% | 4988 |
|
|
2020
Q1 | $116K | Buy |
+130
| New | +$106K | ﹤0.01% | 5127 |
|
|
2018
Q4 | – | Sell |
-20
| Closed | -$12K | – | 6687 |
|
|
2018
Q3 | $12K | Sell |
20
-4
| -17% | -$2.44K | ﹤0.01% | 6272 |
|
|
2018
Q2 | $10K | Hold |
24
| – | – | ﹤0.01% | 6309 |
|
|
2018
Q1 | $18K | Hold |
24
| – | – | ﹤0.01% | 6150 |
|
|
2017
Q4 | $25K | Buy |
+24
| New | +$42.2K | ﹤0.01% | 6021 |
|
Other funds holding PAVM
TSC
SS
Morgan Stanley's PAVM Position: Q2 2026 in Review
Morgan Stanley reduced its PAVmed (PAVM) stake by 1.2% in Q2 2026, selling an estimated $14 and leaving 163 shares worth $968. The position accounts for ﹤0.01% of the portfolio, ranked #7516.
Morgan Stanley first reported a position in PAVM in Q4 2017 and has held it in 30 quarters since. The position peaked at $9.73M in Q3 2021. 19 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.
- Morgan Stanley held 163 shares of PAVmed worth $968 as of Q2 2026.
- Morgan Stanley sold 2 PAVmed shares in Q2 2026, an estimated $14.
- PAVmed made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7516 holding.
- Morgan Stanley first reported a position in PAVmed in Q4 2017 and has held it in 30 quarters since.
- Morgan Stanley's PAVmed position peaked at $9.73M in Q3 2021.
- 19 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.